Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients

Table 1 Crude and adjusted prevalence^a of HCV testing, positivity, cured or cleared, and last RNA positive waiting for treatment, according to sex

	General population		Diabetic population		AS patients
	Crude (95%CI)	Adjusted (95%CI)	Crude (95%CI)	Adjusted (95%CI)	Crude (95%CI)	Adjusted (95%CI)
HCV tested
Female	148.7 (147.2–150.1)	152.4 (151.1–153.7)	143.8 (137.8–150.1)	179.1 (164.7–193.6)	555.6 (490.1–626.6)	451.4 (390.3–512.5)
Male	79.8 (79.7–80.9)	78.4 (77.3–79.4)	132.7 (127.4–138.2)	122.9 (109.0–136.8)	461.1 (433.5–490.0)	367.8 (336.9–398.8)
HCV positive
Female	6.0 (5.7–6.3)	5.4 (5.1–5.7)	12.5 (10.7–14.4)	8.2 (6.2–10.3)	184.5 (148.0–227.3)	123.8 (96.4–151.2)
Male	7.0 (6.7–7.3)	6.6 (6.3–6.9)	12.6 (11.0–14.4)	10.8 (8.6–13.1)	163.6 (147.3–181.2)	113.0 (99.8–126.2)
Cured or cleared
Female	677.5 (629.3–728.4)	692.2 (644.5–739.9)	644.1 (507.5–806.1)	337.1	571.4 (390.9–807.7)	458.4
Male	735.8 (689.3–784.6)	746.2 (716.1–776.3)	756.0 (630.2–899.4)	526.4	726.7 (625.9–838.8)	432.5
Last RNA+ waiting for treatment
Female	317.0 (284.3–352.4)	304.0 (256.3–351.6)	347.5 (249.3–471.4)	191.1	392.9 (246.2–594.8)	176.2
Male	246.8 (220.0–275.8)	234.5 (204.8–264.1)	220.2 (155.1–303.6)	121.2	230.5 (175.4–297.3)	295.3

ISSN: 1750-9378